Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

Sadiq AA, Geynisman DM, Salgia R.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1810-1. doi: 10.1097/01.JTO.0000407568.45147.43. No abstract available.

2.

MET as a possible target for non-small-cell lung cancer.

Sadiq AA, Salgia R.

J Clin Oncol. 2013 Mar 10;31(8):1089-96. doi: 10.1200/JCO.2012.43.9422. Epub 2013 Feb 11. Review.

3.

Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

Sadiq AA, Salgia R.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S372-4. doi: 10.1097/JTO.0b013e31826df03e. Review. No abstract available.

4.

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

Riess JW, Neal JW.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1797-8. doi: 10.1097/01.JTO.0000407562.07029.52. No abstract available.

5.

MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.

Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ.

Pharmacol Res. 2015 Dec;102:90-106. doi: 10.1016/j.phrs.2015.09.016. Epub 2015 Sep 28. Review. No abstract available.

PMID:
26413995
6.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
7.

Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.

Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA.

Clin Cancer Res. 2013 Oct 15;19(20):5699-710. doi: 10.1158/1078-0432.CCR-13-1758. Epub 2013 Aug 29.

8.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.

Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.

PMID:
25502629
9.

The current state of molecularly targeted drugs targeting HGF/Met.

Yano S, Nakagawa T.

Jpn J Clin Oncol. 2014 Jan;44(1):9-12. doi: 10.1093/jjco/hyt188. Epub 2013 Dec 25.

10.

The emerging role of MET/HGF inhibitors in oncology.

Scagliotti GV, Novello S, von Pawel J.

Cancer Treat Rev. 2013 Nov;39(7):793-801. doi: 10.1016/j.ctrv.2013.02.001. Epub 2013 Feb 28. Review.

PMID:
23453860
11.

C-MET inhibitors in the treatment of lung cancer.

Goździk-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R.

Curr Treat Options Oncol. 2014 Dec;15(4):670-82. doi: 10.1007/s11864-014-0313-5. Review.

PMID:
25266653
12.

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

Robinson KW, Sandler AB.

Oncologist. 2013;18(2):115-22. doi: 10.1634/theoncologist.2012-0262. Epub 2013 Jan 23. Review.

13.

Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Surati M, Patel P, Peterson A, Salgia R.

Expert Opin Biol Ther. 2011 Dec;11(12):1655-62. doi: 10.1517/14712598.2011.626762. Review.

14.

Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.

Kunii E, Ozasa H, Oguri T, Maeno K, Fukuda S, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Niimi A.

Anticancer Res. 2015 Oct;35(10):5241-7.

PMID:
26408683
15.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

16.

Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET....

Scagliotti GV, Di Maio M.

Ann Oncol. 2015 Oct;26(10):2007-9. doi: 10.1093/annonc/mdv334. Epub 2015 Aug 11. No abstract available.

PMID:
26265168
17.

High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.

To C, Seiden I, Liu N, Wigle D, Tsao MS.

Exp Cell Res. 2002 Feb 1;273(1):45-53.

PMID:
11795945
18.

MET and ALK as targets for the treatment of NSCLC.

Capelletti M, Gelsomino F, Tiseo M.

Curr Pharm Des. 2014;20(24):3914-32. Review.

PMID:
24138716
19.

Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.

20.

Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.

Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS.

Neoplasia. 2009 Dec;11(12):1292-300.

Items per page

Supplemental Content

Write to the Help Desk